{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:07:23Z","timestamp":1789056443182,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172253"],"award-info":[{"award-number":["82172253"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82400707"],"award-info":[{"award-number":["82400707"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82100636"],"award-info":[{"award-number":["82100636"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","award":["2025ZD01905804"],"award-info":[{"award-number":["2025ZD01905804"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Advances"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omta.2026.201790","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:15:19Z","timestamp":1781828119000},"page":"201790","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and HBsAg reduction with a lentiviral vaccine J-51 in chronic hepatitis B: An investigator-initiated pilot trial"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4874-3199","authenticated-orcid":false,"given":"Jieyu","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiran","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongrong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingmei","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9571-7347","authenticated-orcid":false,"given":"Fang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linshu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omta.2026.201790_bib1","unstructured":"Organization, W.H. (2025). Hepatitis B. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b."},{"key":"10.1016\/j.omta.2026.201790_bib2","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jhep.2025.03.018","article-title":"EASL Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"83","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.omta.2026.201790_bib3","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","article-title":"HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability","volume":"63","author":"Kim","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.omta.2026.201790_bib4","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jhep.2018.10.014","article-title":"HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues","volume":"70","author":"Yip","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.omta.2026.201790_bib5","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/apt.16659","article-title":"Systematic review with meta-analysis: the impact of functional cure on clinical outcomes in patients with chronic hepatitis B","volume":"55","author":"Vittal","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.omta.2026.201790_bib6","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jhep.2023.06.002","article-title":"Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference","volume":"79","author":"Ghany","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.omta.2026.201790_bib7","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.jhep.2021.04.051","article-title":"Ubiquitous expression of HBsAg from integrated HBV DNA in patients with low viral load","volume":"75","author":"Meier","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.omta.2026.201790_bib8","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jhep.2016.05.014","article-title":"Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients","volume":"65","author":"Boyd","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.omta.2026.201790_bib9","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/j.1365-2036.2005.02453.x","article-title":"The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation","volume":"21","author":"van Zonneveld","year":"2005","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.omta.2026.201790_bib10","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.gastro.2015.09.043","article-title":"Combination of Tenofovir Disoproxil Fumarate and Peginterferon alpha-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B","volume":"150","author":"Marcellin","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.omta.2026.201790_bib11","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.jhep.2016.01.026","article-title":"Adaptive immunity in HBV infection","volume":"64","author":"Bertoletti","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.omta.2026.201790_bib12","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1053\/j.gastro.2019.03.044","article-title":"Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis","volume":"157","author":"Boni","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.omta.2026.201790_bib13","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1080\/21645515.2019.1651141","article-title":"Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial","volume":"16","author":"Zoulim","year":"2020","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.omta.2026.201790_bib14","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/mt.2013.274","article-title":"Immunological and antiviral responses after therapeutic DNA immunization in chronic hepatitis B patients efficiently treated by analogues","volume":"22","author":"Godon","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201790_bib15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/CJI.0000000000000067","article-title":"Virological and preclinical characterization of a dendritic cell targeting, integration-deficient lentiviral vector for cancer immunotherapy","volume":"38","author":"Odegard","year":"2015","journal-title":"J. Immunother."},{"key":"10.1016\/j.omta.2026.201790_bib16","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/s42003-021-02251-6","article-title":"Lentiviral vector induces high-quality memory T cells via dendritic cells transduction","volume":"4","author":"Ku","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.omta.2026.201790_bib17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jhep.2023.09.019","article-title":"Therapeutic vaccination with lentiviral vector in HBV-persistent mice and two inactive HBsAg carriers","volume":"80","author":"Zhang","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.omta.2026.201790_bib18","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s12072-025-11001-3","article-title":"The incidence of spontaneous HBsAg loss in patients with different baseline HBsAg levels: a systematic review and meta-analysis","volume":"20","author":"Sui","year":"2026","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.omta.2026.201790_bib19","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1097\/HEP.0000000000000741","article-title":"Hepatitis B surface antigen seroclearance is uncommon but durable in the long run","volume":"79","author":"Yip","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.omta.2026.201790_bib20","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1056\/NEJMoa2210027","article-title":"Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection","volume":"387","author":"Yuen","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201790_bib21","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1056\/NEJMoa2405485","article-title":"Xalnesiran with or without an Immunomodulator in Chronic Hepatitis B","volume":"391","author":"Hou","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201790_bib22","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1056\/NEJMra2211764","article-title":"New Approaches to Chronic Hepatitis B","volume":"388","author":"Dusheiko","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201790_bib23","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/mt.2015.194","article-title":"Development of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5-based Constructs","volume":"24","author":"Alonso-Padilla","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201790_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-016-1111-6","article-title":"Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response","volume":"15","author":"Edwards","year":"2017","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.omta.2026.201790_bib25","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.4049\/jimmunol.1601877","article-title":"Induction of an IFN-Mediated Antiviral Response by a Self-Amplifying RNA Vaccine: Implications for Vaccine Design","volume":"198","author":"Pepini","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.omta.2026.201790_bib26","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1053\/j.gastro.2023.01.005","article-title":"Low Hepatitis B Core-Related Antigen Levels Correlate Higher Spontaneous Seroclearance of Hepatitis B Surface Antigen in Chronic Hepatitis B Patients With High Hepatitis B Surface Antigen Levels","volume":"164","author":"Tseng","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.omta.2026.201790_bib27","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.jhep.2020.11.003","article-title":"Transition to HBeAg-negative chronic hepatitis B virus infection is associated with reduced cccDNA transcriptional activity","volume":"74","author":"Suslov","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.omta.2026.201790_bib28","doi-asserted-by":"crossref","DOI":"10.1172\/JCI163175","article-title":"Functional cure of hepatitis B requires silencing covalently closed circular and integrated hepatitis B virus DNA","volume":"132","author":"Ghany","year":"2022","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omta.2026.201790_bib29","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1136\/gutjnl-2024-333026","article-title":"Long-term hepatitis B surface antigen response after finite treatment of ARC-520 or JNJ-3989","volume":"74","author":"Mak","year":"2025","journal-title":"Gut"}],"container-title":["Molecular Therapy Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26001254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26001254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:18:03Z","timestamp":1789053483000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3117387X26001254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S3117387X26001254"],"URL":"https:\/\/doi.org\/10.1016\/j.omta.2026.201790","relation":{},"ISSN":["3117-387X"],"issn-type":[{"value":"3117-387X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and HBsAg reduction with a lentiviral vaccine J-51 in chronic hepatitis B: An investigator-initiated pilot trial","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omta.2026.201790","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201790"}}